Loading
Cells without an engineered receptor: tumour-infiltrating lymphocytes, natural killer cells, cord blood grafts and virus-specific T cells, from the patient or from a donor. The grid below is cell type against cell source: 7 by 2 from 29 medicines, 5 combinations approved, 6 in development, 0 tried and stopped, 5 untried in this corpus.
| Medicines | Records | Stopped, and why | ||||||
|---|---|---|---|---|---|---|---|---|
| Tumour-infiltrating lymphocytes | Autologous | Approved | 1 | 8 | 1 | A phase 1 trial of ITIL-168 run by Instil Bio, withdrawn before enrolling. and 3 more recorded reasons | ||
| Tumour-infiltrating lymphocytes | Cell source not recorded | In development | 0 | 1 | 0 | - | ||
| T cells (unspecified) | Autologous | In development | 0 | 6 | 0 | - | ||
| T cells (unspecified) | Allogeneic | In development | 0 | 1 | 0 | A phase 1 trial of Rivogenlecleucel run by Fred Hutchinson Cancer Center, withdrawn before enrolling. and 2 more recorded reasons | ||
| NK cell | Autologous | In development | 0 | 1 | 0 | - | ||
| NK cell | Allogeneic | In development | 0 | 3 | 0 | A phase 1/2 trial of CYNK-001 run by Celularity Incorporated, withdrawn before enrolling. | ||
| NK cell | Cell source not recorded | Approved | 1 | 1 | 0 | Terminated, with no reason given on the registry; no results posted. | ||
| Cord blood stem cells | Allogeneic | Approved | 2 | 0 | 0 | - | ||
| Mesenchymal stromal cells | Allogeneic | Approved | 1 | 0 | 0 | - | ||
| Regulatory T cells | Autologous | In development | 0 | 1 | 0 | - | ||
| Virus-specific T cells | Allogeneic | Approved | 1 | 0 | 0 | - |
CHMP negative opinion 25 Jun 2026 on Tacquell (autologous TIL; applicant Netherlands Cancer Institute) for melanoma
EMA / European Commission (EU): rejected 2026 · regulator row
CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute
A phase 1/2 trial of CYNK-001 run by Celularity Incorporated, withdrawn before enrolling.
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type: phase 1/2, terminated or withdrawn · trial record
A phase 1 trial of ITIL-168 run by Instil Bio, withdrawn before enrolling.
ITIL-168 in Advanced Solid Tumors: phase 1, terminated or withdrawn · trial record
A phase 1 trial of Rivogenlecleucel run by Fred Hutchinson Cancer Center, withdrawn before enrolling.
A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies: phase 1, terminated or withdrawn · trial record
A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT: phase 1, terminated or withdrawn · trial record
Terminated, with no reason given on the registry; no results posted.
MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing)
EMA / European Commission (EU): withdrawn 2025 · regulator row
These medicines belong to the format but their cell type is on no record the engine reads: the targets field is empty, the target lists no such drug, the trials linked to it name no target of its own, and the modality, mechanism and summary text name none the corpus knows. They are listed here rather than placed by guesswork; adding the cell type to the record puts them in the grid on the next build.
Each medicine's parts come from its own record: the targets field first, else the target records that list the medicine, else a sibling conjugate that shares its antibody name, else the trials linked to it, else the target names the corpus knows found in its modality, mechanism or summary text. The second part is read from the medicine's technology links first and from its modality and mechanism text second; a part no record names is shown as not recorded. Every part carries the fields it was read from and a confidence in the JSON file.
Approved: a medicine in the cell has an approval row or a regulator's approved entry and is not recorded as withdrawn. In development: a recruiting, active or planned trial, a development-phase record status, or active studies in the ClinicalTrials.gov index, and no approval. Tried and stopped: every medicine in the cell is withdrawn, negative or historic, or its only trial evidence is a terminated, withdrawn or negative study, or its approval was withdrawn. Untried: no medicine in this corpus combines the two parts.
A cell is coloured by its strongest medicine; the table shows each medicine with its own state. The reasons quoted under Stopped, and why are the records' words, including the registry's whyStopped text where the sponsor wrote one, and include stopped studies of medicines that are still in development elsewhere. Nothing here is medical advice.